[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609358":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":56,"collaborators":25,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":25,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":25,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":25,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Medical University of South Carolina","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Remimazolam followed by Propofol","ACTIVE_COMPARATOR","Patients will be randomized to receive Remimazolam 0.075 mg\u002Fkg (maximum of 5 mg) for sedation during their first laser therapy session, then 4-6 weeks later at their next laser therapy session they will receive propofol 0.8 mg\u002Fkg IV bolus for sedation.",[13,14],"Drug: Remimazolam besylate","Drug: Propofol",{"label":16,"type":10,"description":17,"interventionNames":18},"Propofol followed by Remimazolam","Patients will be randomized to receive Propofol 0.8 mg\u002Fkg IV bolus for sedation during their first laser therapy session, then 4-6 weeks later at their next laser therapy session they will receive Remimazolam 0.075 mg\u002Fkg (maximum of 5 mg) for sedation.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Remimazolam besylate","Remimazolam",[16,9],null,{"type":21,"name":27,"description":27,"armGroupLabels":28,"otherNames":25},"Propofol",[16,9],[30],{"name":31,"affiliation":5,"role":32},"Rishi Patel, MD","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Haley Nitchie","CONTACT","(843) 792-1869","nitchie@musc.edu",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Charleston","South Carolina","29425","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-79.93275,32.77632,{"lat":51,"lon":50},[54],{"name":55,"role":32,"phone":25,"phoneExt":25,"email":25},"Rishi Patel, M.D.",{"type":32,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Rishi Patel","Assistant Professor-Faculty","100609358","phase-4-remimazolam-vs-propofol-in-laser-burn-cases-100609358",false,"NCT07213544","Remimazolam vs Propofol in Laser Burn Cases","Comparison of Remimazolam Versus Propofol for Monitored Anesthetic Care in Elective Fractional Ablative CO₂ Laser","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Undergoing both outpatient Session #1 and Session #2 of fractional ablative CO2 laser therapy\n\nExclusion Criteria:\n\n* History of previous fractional ablative laser therapy for burn scar\n* Procedure expected to last longer than 30 minutes\n* Allergy such as dextran 40 or contraindication to either of the study drugs\n* Pregnant and\u002For breastfeeding\n* Subjects who are unable to or choose not to give informed consent","ALL","18 Years",{"count":69,"type":70},136,"ESTIMATED","INTERVENTIONAL",[73],"PHASE4","This randomized, single-blind, crossover study compares remimazolam and propofol for monitored anesthetic care during fractional ablative CO₂ laser therapy for burn scars. The primary aim is to assess incidence of respiratory depression, defined as a need for advanced airway maneuvers (jaw thrust\u002Fchin lift, insertion of oral or nasal airway, or bag mask ventilation), and hypopnea (respiratory rate \\\u003C 8).",[76,77,78],"Burn Scar","Hypertrophic Scarring","Procedural Sedation","2025-11-17",{"date":81,"type":82},"2025-11-20","ACTUAL",{"date":84,"type":82},"2025-11-12",{"date":86,"type":70},"2027-01-01",{"name":5,"class":6},1]